BioPharma Reporter and Outsourcing Pharma is keeping you in the know with our most recent round-up of important appointments in the pharma industry - including Veranova, Matica Bio and Aldevron.
Mural Health Technologies, Inc. has raised $8 million in seed funding for the growth of its Mural link platform it says is aimed at ‘modernizing the clinical trial experience for both patients and caregivers’.
Exscientia plc will receive an upfront cash payment of $20 million from Merck KGaA, Darmstadt, Germany, as the companies collaborate plus potential payments of up to $674 million in aggregate.
A study of MedRhythm’s MR-001 neurorehabilitation system, designed to improve walking and ambulation in adults with chronic stroke impairment, will use Curavit Clinical Research as its virtual contract research organization (VCRO).
Built upon seven years of real-world patient journey data, Belong.Life has recently announced the launch of its software as a service (SaaS)-based conversational artificial intelligence (AI) cancer clinical trial matching platform.
Therapeutic candidates and patient samples can be analyzed ‘in a fraction of the time it would normally take’ thanks to newly patented single-molecule imaging technology.
This week's woman in science, is Maria Pereira, who leads the Innovation Hub at TISSIUM, a Paris-based medtech startup that develops solutions for tissue reconstruction.
Qunaterix' LucentAD test could reveal whether a person is likely to have Alzheimer's Disease or not. In an interview with company CEO, Masoud Toloue, he explains the science and motivation behind the test.
The Japanese firm Astellas Pharma will apply for planning permission to construct a drug manufacturing facility in Tralee, Co. Kerry, Ireland worth around €330 million ($352 million).
The small molecule drug Ojjaara (momelotinib), developed by GlaxoSmithKline, has become the first U.S. Food and Drug Administration (FDA)-approved treatment for patients with the blood cancer myelofibrosis and anemia.
The French-U.S. company Novadiscovery has hailed a “watershed moment for clinical trial design” as its trial simulation tool successfully predicted the outcome of a phase 3 oncology trial run by AstraZeneca.
The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.
A partnership deal between the Dutch digital health company Congenica and clinical trial platform provider myTomorrows will see the companies pooling their technologies to help more patients receive precision oncology treatments.
Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firm’s small molecule cancer treatment.
The AstraZeneca-owned company Alexion has teamed up with Verge Genomics to deploy the U.S. startup’s drug discovery platform in the search for novel drug targets for rare neurodegenerative and neuromuscular diseases.
The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.
An oral treatment, developed by the U.S. company Crinetics Pharmaceuticals, Inc., has shown promise as an alternative to injected therapies for tackling the rare disease acromegaly in a phase 3 trial.
OSP spoke to Vesta Marciulioniene, director global regulatory clinical services at ICON Biotech, a contract research organisation who shares insights on the new EMA guideline for computerised systems and electronic data in clinical trials and what new...
HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI, has announced the launch of its precision measures platform.
Glasgow diagnostics spinout Microplate Dx has closed a £2.5 million seed funding round to develop its point-of-care diagnostic platform, which can confirm the presence of bacteria and rapidly identify effective antibiotics to use and which ones to avoid....
The U.S. company Nimbus Therapeutics has raised $210 million in a financing round to fund the development of small molecule drugs powered by computational drug discovery.
A benchtop DNA sequencer developed by the U.S. DNA sequencing company Element Biosciences, Inc., has seen sales grow by triple digits and has received more than 100 orders since its launch in March 2022.
The UK organ-on-a-chip (OOC) company CN Bio has teamed up with LifeNet Health LifeSciences to gain access to the non-profit tissue bank’s validated human cells for use in organ models for life sciences research.
CymaBay announced recently the initiation of its 52-week, placebo-controlled, randomized, phase 3 study — 'Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase (ALP) Levels in subjects with Primary Biliary Cholangitis...
The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnson’s pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.
Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying...
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
